Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP
Average trade mark-up on these drugs now around 170%, reaching 700% in some cases; intervention to cut prices by up to 70% of MRP, resulting in cumulative annual savings of ₹2,500 crore for patients
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.thehindu.com — the content belongs to The Hindu - Sci-Tech.
